Seattle Biotech Tune Therapeutics Aims to Cure Hepatitis B with Breakthrough Gene Therapy

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses responsible for the world’s most common serious liver infections and cancers. Unlike current treatments which only slow HBV’s progression, Tune Therapeutics’ epigenetic approach aims to eliminate the virus’ ability to replicate, potentially offering a cure for millions.